Patents by Inventor Mako Ogino

Mako Ogino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-human TSLP receptor antibody
    Patent number: 9908941
    Abstract: An anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. A method for preventing or treating asthma by administering the anti-human TSLP receptor antibody or an antigen-binding fragment thereof. An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: March 6, 2018
    Assignee: Astellas Pharma Inc.
    Inventors: Hiromu Sato, Daisuke Yamajuku, Kazunori Arai, Mako Ogino
  • NOVEL ANTI-HUMAN TSLP RECEPTOR ANTIBODY
    Publication number: 20160208005
    Abstract: An anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. A method for preventing or treating asthma by administering the anti-human TSLP receptor antibody or an antigen-binding fragment thereof. An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model.
    Type: Application
    Filed: April 4, 2016
    Publication date: July 21, 2016
    Applicant: Astellas Pharma Inc.
    Inventors: Hiromu SATO, Daisuke Yamajuku, Kazunori Arai, Mako Ogino
  • Anti-human TSLP receptor antibody
    Patent number: 9328171
    Abstract: [Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. [Means for Solution] An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model, and then the present invention was completed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 3, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Hiromu Sato, Daisuke Yamajuku, Kazunori Arai, Mako Ogino
  • NOVEL ANTI-HUMAN TSLP RECEPTOR ANTIBODY
    Publication number: 20160046720
    Abstract: [Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. [Means for Solution] An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model, and then the present invention was completed.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Applicant: Astellas Pharma Inc.
    Inventors: Hiromu SATO, Daisuke Yamajuku, Kazunori Arai, Mako Ogino